{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.0","value":"9.0"},{"groupId":"OG001","spread":"8.4","value":"9.8"},{"groupId":"OG002","spread":"8.1","value":"9.5"}]}]}],"denomUnitsSelected":"Number of Surgeries","denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"26"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"27"}],"units":"Number of Surgeries"}],"description":"Thirty participants who underwent surgery (31 surgeries) were determined to have neuropathic pain. Four participants received only opioids for NP and 26 participants (for 27 surgeries) were treated with NP specific medications including gabapentin, tricyclic antidepressant, methadone. One participant had 2 different surgical procedures and was analyzed both in the limb sparing group and in the amputation group.","dispersionType":"Standard Deviation","groups":[{"description":"Participants had metastatic disease at diagnosis.","id":"OG000","title":"Amputation Group"},{"description":"Participants had localized disease at diagnosis. One participant had 2 surgeries.","id":"OG001","title":"Limb Sparing Group"},{"description":"Participants enrolled on the study who met the criteria for evaluation of neuropathic pain.","id":"OG002","title":"Entire Study Group"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"From surgery until resolution of NP symptoms, up to 6 months","title":"Mean Duration of Neuropathic Pain Medication","type":"OTHER_PRE_SPECIFIED","typeUnitsAnalyzed":"Number of Surgeries","unitOfMeasure":"Weeks"}